Synthesis of transferrin (Tf) conjugated liposomes via Staudinger ligation.
Staudinger ligation was evaluated as a strategy for synthesizing receptor targeted liposomes. First, an activated lipid derivative was synthesized by reacting dioleoyl phosphatidylethanolamine (DOPE) and 2-(diphenylphosphino) terephthalic acid 1-methyl 4-penta-fluorophenyldiester. Second, transferrin (Tf) was activated with p-azidophenyl isothiocyanate. Third, liposomes containing the activated lipid were prepared and then coupled to the activated Tf via the Staudinger reaction. These liposomes were evaluated in KB cells for cellular uptake and cytotoxicity, and in mice for pharmacokinetic properties. Tf-derivatized liposomes encapsulating calcein prepared by this conjugation method effectively targeted Tf receptor expressing KB cells. In addition, the Tf-targeted liposomes entrapping doxorubicin showed greatly enhanced in vitro cytotoxicity relative to non-targeted control liposomes. Pharmacokinetic parameters indicated that these liposomes retained long circulating properties relative to the free drug. In summary, Staudinger ligation is an effective method for the synthesis of receptor targeted liposomes.
Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Songlin
S
Xu
Ying
Y
Liu
Heng-Chiat
HC
Tai
Jing
J
Zhu
Hong
H
Ding
Robert J
RJ
Lee
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics; D001386:Azides / Q000737:chemistry; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics; D004337:Drug Carriers; D004339:Drug Compounding; D004705:Endocytosis; D005260:Female; D006801:Humans; D020128:Inhibitory Concentration 50; D007275:Injections, Intravenous; D017879:Isothiocyanates / Q000737:chemistry; D008081:Liposomes; D051379:Mice; D008813:Mice, Inbred ICR; D036103:Nanotechnology; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology; D009946:Organothiophosphorus Compounds / Q000737:chemistry; D010714:Phosphatidylethanolamines / Q000737:chemistry*; D011990:Receptors, Transferrin / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000379:methods; D014168:Transferrin / Q000737:chemistry* / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; D001386:Azides; D004337:Drug Carriers; D017879:Isothiocyanates; D008081:Liposomes; D009946:Organothiophosphorus Compounds; D010714:Phosphatidylethanolamines; D011990:Receptors, Transferrin; D014168:Transferrin; C094877:dioleoyl phosphatidylethanolamine; C035136:4-azidophenylisothiocyanate; D004317:Doxorubicin